AMGEN INC - 19 Sep 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role: 10%+ Owner
Signature: /s/ Peter H. Griffith, Executive Vice President and Chief Financial Officer
Issuer symbol: NMRA
Transactions as of: 19 Sep 2023
Net transactions value: +$29,999,985
Form type: 4
Filing time: 19 Sep 2023, 19:52:07 UTC
Previous filing: 14 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NMRA	Common Stock	Conversion of derivative security		+33,603,948			33,603,948	19 Sep 2023	Direct	F1
transaction	NMRA	Common Stock	Purchase	$29,999,985	+1,764,705	+5.3%	$17.00^*	35,368,653	19 Sep 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NMRA	Series A-2 Preferred Stock	Conversion of derivative security		-32,754,291	-100%		0	19 Sep 2023	Common Stock	32,754,291		Direct	F1
transaction	NMRA	Series B Preferred Stock	Conversion of derivative security		-849,657	-100%		0	19 Sep 2023	Common Stock	849,657		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.